Clinical trials
Unresectable Hepatocellular Carcinoma clinical trials
Below are recruiting unresectable hepatocellular carcinoma clinical trials, each written for real people, not researchers. We’re tracking 157 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07197554RecruitingPhase 1
A study of an experimental drug for advanced solid tumors
This trial tests a new drug, ST-01156, designed to attack cancer cells by breaking down a protein called RBM39. It may be an option for people with advanced solid tumors that have not responded to other treatments.
Duarte, CaliforniaAges 16 years+ - NCT07284121Recruiting
Patient satisfaction and safety of Atezolizumab in routine care
This study tracks how well Atezolizumab (Tecentriq) works for people with certain lung or liver cancers in everyday medical practice. It helps doctors understand if patients are satisfied with their treatment and how it affects their quality of life.
KremsAges 18 years+ - NCT07327034RecruitingPhase 2
ABSK-011 with standard care for advanced liver cancer
This trial tests a new drug, ABSK-011, combined with standard care, against a placebo with standard care for people with advanced liver cancer that has a specific marker called FGF19 overexpression. The goal is to see if ABSK-011 can help slow the disease.
Hefei, AnhuiAges 18 years+ - NCT07365930Recruiting
TIPS treatment support for liver cancer patients on Atezo + Bev
This study looks at whether adding TIPS (a procedure to reduce fluid buildup) to standard immunotherapy (atezolizumab and bevacizumab) helps people with advanced liver cancer who also have cirrhosis. It's for patients whose cancer cannot be removed by surgery or has progressed after other local treatments.
Düsseldorf, North Rhine-WestphaliaAges 18 years+ - NCT07376707RecruitingPhase 1
Study of TGI-5 alone or with nivolumab for advanced solid tumors
This trial tests a new drug called TGI-5, either by itself or combined with another drug (nivolumab), for people with advanced cancer that hasn't responded to standard treatments. It's looking for patients with certain types of solid tumors, especially colorectal, melanoma, lung, or others that have stopped responding to therapy.
ShanghaiAges 18 years+ - NCT07422753RecruitingPhase 2
TACE with immunotherapy drugs for advanced liver cancer
This trial tests a combination of TACE (a procedure that blocks blood supply to the tumor) plus three immunotherapy drugs (sintilimab, bevacizumab, ipilimumab) for people with advanced liver cancer that cannot be removed by surgery. The goal is to see if this combination works better than TACE alone.
Hangzhou, ZhejiangAges 18–75 - NCT07500220RecruitingPhase 1/Phase 2
Dual-target CAR-NK cell therapy for advanced liver cancer
This trial tests a new cell therapy made from natural killer (NK) cells that are engineered to attack two targets (GPC3 and B7-H3) found on liver cancer cells. It may be an option for people with advanced liver cancer who have already tried standard treatments.
Shenzhen, GuangdongAges 18–75 - NCT07639138RecruitingPhase 2
Lenalidomide with targeted therapy and immunotherapy for advanced liver cancer
This trial tests whether adding lenalidomide (a drug that boosts the immune system) to your current targeted therapy and immunotherapy can help advanced liver cancer that has progressed after previous treatments. You would be eligible if your cancer has already been treated with at least two prior drug combinations and initially responded before growing back.
Beijing, No. 1 Shuaifuyuan, Dongcheng District, Beijing, ChinaAges 18–75 - NCT07658833Recruiting
Combined therapy for large liver cancer with vein clot
This trial combines a targeted drug and immunotherapy with procedures that deliver cancer-killing beads or chemotherapy directly to your liver tumor. It is designed for people with large, inoperable liver cancer that has spread into the main vein leading to the heart.
Guangzhou, None SelectedAges 18–75 - NCT07290764Enrolling by invitation
Surgery vs observation for liver cancer that responded to drug therapy
This trial looks at whether people with an initially untreatable liver cancer that has shrunk or disappeared after drug therapy should have surgery or just continue monitoring. It aims to see which approach helps people live longer.
Fuzhou, FujianAges 18–75 - NCT07052448Enrolling by invitation
Radiation after triple therapy for liver cancer
This trial tests whether adding radiation therapy after a combination of three treatments (like immunotherapy and targeted therapy) can help people with liver cancer that cannot be surgically removed. It may be a good option if your tumor responded to the triple therapy but you still cannot have surgery.
Fuzhou, FujianAges 18–75 - NCT05441475Enrolling by invitationPhase 2
Trial for advanced liver cancer using ABSK-011 plus atezolizumab
This Phase 2 study tests ABSK-011 combined with either atezolizumab or the usual care in people with advanced or unresectable liver cancer. It aims to see if the treatment helps shrink tumors and control the cancer when standard options aren’t working or can’t be used.
Hubei, Shanghai MunicipalityAges 18 years+ - NCT07276100RecruitingPhase 2
Fecal transplant to help liver cancer that worsened on first treatment
This trial tests whether transplanting healthy stool bacteria into your gut can help your own immune system fight liver cancer that has stopped responding to the standard first combination treatment (atezolizumab + bevacizumab). It is for patients whose liver cancer has started growing quickly despite that treatment.
Bologna, BOAges 18 years+
Hear when a new Unresectable Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for unresectable hepatocellular carcinoma?
- Yes. Clin2 currently lists 157 recruiting unresectable hepatocellular carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a unresectable hepatocellular carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a unresectable hepatocellular carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.